Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GERICO11_Adjuvant systemic treatment for ER-positive HER2-negative breast carcinoma in women over 70 according to Genomic Grade
2024-516996-34-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Sep 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of doxorubicin, cyclophosphamide and docetaxel in breast cancer (2 arms), sponsored by Unicancer. Primary endpoint: Overall survival. Planned start Sep 2024; status: authorised.
02
Drugs
doxorubicincyclophosphamidedocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-516996-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516996-34-00.